Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) EBITDA (2016 - 2025)

iBio (IBIO) has disclosed EBITDA for 16 consecutive years, with -$9.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 105.5% to -$9.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.8 million, a 61.03% decrease, with the full-year FY2025 number at -$18.6 million, down 11.83% from a year prior.
  • EBITDA was -$9.0 million for Q4 2025 at iBio, down from -$5.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$3.4 million in Q2 2024 to a low of -$10.6 million in Q4 2022.
  • A 5-year average of -$6.3 million and a median of -$5.5 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 222.26% in 2021, then soared 57.48% in 2023.
  • iBio's EBITDA stood at -$7.2 million in 2021, then tumbled by 46.22% to -$10.6 million in 2022, then skyrocketed by 57.48% to -$4.5 million in 2023, then rose by 2.94% to -$4.4 million in 2024, then plummeted by 105.5% to -$9.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's EBITDA are -$9.0 million (Q4 2025), -$5.7 million (Q3 2025), and -$5.2 million (Q2 2025).